SELLAS Life Sciences Group, Inc. Common Stock
Here’s whether SELLAS Life Sciences Group, Inc. Common Stock (SLS) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+12.10% over 10 days); RSI 50 — healthy momentum range; strong 1-year return of +374.6%; 3-month momentum positive (+46.1%). Concerns: declining volume on rally — weak conviction (0.74x 30d avg). Currently 17.7% off its 52-week high. Score: +6/7.
SLS is in a confirmed uptrend, trading above both its 50-day ($6.26) and 200-day ($3.78) moving averages. An RSI of 50.4 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +374.6% compares to +22.9% for SPY (beat the market by 351.7%).